MET先锋派 | 实力领航！卡马替尼照亮METex14跳突晚期NSCLC患者生命之路

参考文献：

[1] Mazieres J, Vioix H, Pfeiffer BM, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer. 2023. 24(6): 483-497.

[2] OFFIN M, LUO J, GUO R, et al. CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib[J]. JCO Precis Oncol, 2020,4:PO.20.00098.

[3] 郑荣寿, 陈茹, 韩冰峰,等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志,2024,46(3):221-231.

[4] CHINESE ANTI-CANCER ASSOCIATION C O L C S, , LUNG CANCER GROUP OF ONCOLOGY BRANCH C M A, et al. [Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage Ⅲ non-small cell lung cancer (2019)][J]. Zhonghua Zhong Liu Za Zhi, 2019,41(12):881-890.

[5] BALTSCHUKAT S, ENGSTLER B S, HUANG A, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation[J]. Clin Cancer Res, 2019,25(10):3164-3175.

[6] WOLF J, GARON E B, GROEN H J M, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021,39(15_suppl):9020-9020.

[7] WOLF J, GARON E B, GROEN H J M, et al. 26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1[J]. ANNALS OF ONCOLOGY, 2022,33:S42.

[8] WU Y, ZHAO J, HU J, et al. 388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study[J]. ANNALS OF ONCOLOGY, 2022,33:S1593.

[9] FUJINO T, KOBAYASHI Y, SUDA K, et al. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro[J]. J Thorac Oncol, 2019,14(10):1753-1765.

[10] WOLF J, HOCHMAIR M, HAN J Y, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial[J]. Lancet Oncol, 2024,25(10):1357-1370.

[11] 《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》http://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=de66e92b7edd4056ac41c0c4d3c011f3.pdf .

[12] THOMAS M, GARASSINO M, FELIP E, et al. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C[J]. Journal of Thoracic Oncology, 2022,17(9):S9-S10.

[13] SAKAI H, MORISE M, KATO T, et al. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study[J]. Jpn J Clin Oncol, 2021,51(8):1261-1268.

[14] DRILON A, CLARK J W, WEISS J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration[J]. Nat Med, 2020,26(1):47-51.

[15] LU S, YU Y, ZHOU J, et al. Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)[J]. Cancer Res, 2022,82(12_Supplement):CT034-CT034.

[16] YANG J J, ZHANG Y, WU L, et al. Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study[J]. J Clin Oncol, 2024,42(31):3680-3691.

[17]《国家基本医疗保险、工伤保险和生育保险药品目录（2023年）》https://www.mohrss.gov.cn/xxgk2020/fdzdgknr/shbx_4216/gsbx/202401/P020240117600180317106.pdf .

[18] 简明处方：https://www.medlive.cn/recommond.php?kyprojectid=1_002094401_1&hash=DaGO1J

审批码TAB0037455-84543， 有效期至2026-01-07，资料过期，视同作废。

撰写：Leon

审校：Leon

排版：Yian

执行：Aurora

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。